The third drug candidate, THN101, has the potential to improve the treatment of neuropathic pain. Similar to THN201, it combines amitriptyline to act on neuronal activity and mefloquine to act on glial cell activity. This drug candidate is also scheduled to begin clinical development in 2018. THN101 is covered by a family of patents that will expire in 2036 at the earliest.
- Permanent background pain, with occasional stabbing pains, burning sensation and twinges;
- More than 100 causes identified to date;
- A prevalence rate of 7% in the general population (70 million patients in the 7 major markets);
- A market size worth US$ 3B.